Tag: Psoriasis
FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body
Approval is for once-daily 0.3 percent roflumilast topical foam for patients 12 years and older
Residual Inflammation Seen in One-Third of Patients With Psoriasis on Biologics
Residual inflammation significantly linked to higher BMI, metabolic dysfunction-associated steatotic liver disease, baseline systemic inflammation
Flares Occur Frequently in Generalized Pustular Psoriasis
Frequent treatment alterations of off-label biologics and nonsteroidal systemic agents observed
Real-World Study Shows Effectiveness of Ixekizumab for Psoriasis
Significant clinical improvements seen with and without induction therapy, with faster initial response with induction
Childhood Maltreatment May Up Risk for Immune-Mediated Inflammatory Disorders
Significantly higher risk seen for rheumatoid arthritis and psoriasis
High Ultraprocessed Food Intake Linked to Active Psoriasis
Association persists after adjustment for age, BMI, alcohol intake, and comorbidities
Home-Based Phototherapy as Effective as Office-Based for Psoriasis
For plaque or guttate psoriasis, home-based phototherapy noninferior to office-based phototherapy for PGA and DLQI
Racial Differences Identified in Frequency of Biopsy for Psoriasis
Skin biopsies, indicating diagnostic uncertainty, performed most frequently for Black patients
Psoriasis, Psoriatic Arthritis Tied to Higher Risk of Polyneuropathy
However, increased risk seems to be linked to the higher prevalence of contributing factors for polyneuropathy
Air Pollution Exposure Tied to New Psoriasis
Increase in psoriasis risk also seen among those with higher genetic vulnerability and increased exposure to air pollutants
